spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  FLT3 

 HSMN NewsFeed - 20 Jun 2025
Lomond Therapeutics Announces U.S. FDA Clearance of IND Application for Lonitoclax, a Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax and Venetoclax- Like Molecules
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 Mar 2025
Lomond Therapeutics Completes Second and Third Closings and adds Two New Investors
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2021
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Dec 2020
Astellas Reports XOSPATA(R) (gilteritinib) in Combination with Azacitidine Did Not Meet Endpoint of Overall Survival in Newly Diagnosed FLT3 Mutation-Positive Acute Myeloid Leukemia Patients Ineligible for Intensive Induction Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 May 2020
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
Diagnostics Oncology FDA
 HSMN NewsFeed - 30 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 25 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) (gilteritinib) as a Monotherapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 21 Jun 2019
Daiichi Sankyo Provides Update on FDA Review of Quizartinib for the Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2019
U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA(R) (gilteritinib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2019
Daiichi Sankyo Provides Update on Ongoing FDA Review for Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Feb 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Nov 2018
EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Aug 2018
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Relapsed/Refractory FLT3-ITD AML
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jul 2018
Daiichi Sankyo Enters Worldwide Licensing Agreement with Glycotope for Gatipotuzumab Antibody Drug Conjugate
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 May 2018
U.S. FDA Grants Priority Review to Astellas' New Drug Application for Gilteritinib for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2018
Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2017
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Aug 2017
FDA Grants Breakthrough Therapy Designation to Daiichi Sankyo's DS-8201 for HER2-Positive Metastatic Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 28 Aug 2017
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals for a Highly Selective RET Inhibitor for Solid Tumors
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Aug 2017
ArcherDX expands blood-based mutation assay portfolio with new myeloid panels
Diagnostics Product Launch
 HSMN NewsFeed - 28 Apr 2017
Invivoscribe(R) Receives FDA Approval for the LeukoStrat(R) CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt(R) and is the First Companion Diagnostic for AML
Diagnostics Personalized Medicine Oncology FDA
 HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2014
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Apr 2013
Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2012
Pfizer Receives EU Marketing Authorization for INLYTA(R) (Axitinib)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Mar 2012
Synta Announces Appointment of George Farmer, Ph.D., as Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jan 2012
U.S. Food And Drug Administration Approves Pfizer’s INLYTA(R) (axitinib) For Patients With Previously Treated Advanced Renal Cell Carcinoma (RCC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Nov 2011
Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 May 2011
SUTENT(R) Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Apr 2011
Daiichi Sankyo Completes Plexxikon Acquisition
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Dec 2010
SUTENT(R) Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Sep 2010
Pfizer Discontinues Phase 3 Trial of SUTENT(R) in Advanced Castration-Resistant Prostate Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2010
Data Show Progression-Free Survival Advantage with Sutent(R) in Patients with Pancreatic Neuroendocrine Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2009
Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Apr 2009
Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2009
Sutent Significantly Increases Progression Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors, Study Stopped Early
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2007
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2006
Genzyme Releases Two New Molecular Tests for Acute Myelogenous Leukemia
Diagnostics Oncology
Return to NewsFeed  

 Additional items found! 9

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 9 additional stories matching:
FLT3
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!